Abstract. MicroRNA-135a (miR-135a) has been shown to exert important roles in various human cancer types, such as glioblastoma, thyroid carcinoma and renal carcinoma. However, the function of miR-135a in acute myeloid leukemia (AML) remains largely unknown. In the present study, it was demonstrated that miR-135a expression was significantly downregulated in AML cells compared with normal control cells. Furthermore, the downregulation of miR-135a in patients with AML predicted poor prognosis. Through functional experiments, overexpression of miR-135a was demonstrated to significantly inhibit the proliferation and cell cycle of AML cells, while it promoted cellular apoptosis. miR-135a directly targeted HOXA10 in AML cells. miR-135a overexpression significantly suppressed the mRNA and protein levels of HOXA10 in AML cells. Moreover, there was an inverse association between miR-135a expression and HOXA10 level in AML samples. Additionally, ectopic expression of HOXA10, restoration of HOXA10 significantly abolished the effects of miR-135a mimic transfection in AML cells. Taken together, our study identified miR‑135a as a tumor suppressor in AML by targeting HOXA10, and miR-135a may be a promising prognostic biomarker for AML patients.

Introduction

Acute myeloid leukemia (AML) is one kind of hematological malignant cancers and characterized by an incensement of undifferentiated myeloid progenitor cells in peripheral blood and bone marrow (1,2). AML cells were clinically heterogeneous and their progenitor cells have a self-renewal potential to generate the bulk of leukemia cells (3,4). The incidence and mortality are gradually increasing in developing countries (5). In China, the incidence of AML is the highest among young patients (5). Chemotherapy consisting paclitaxel, cisplatin or others is the main approach for AML treatment (6). However, because of therapy resistance, tumor metastasis and recurrence, the outcomes of AML patients remain very poor (7). AML has become a great problem for public health. Thus, it is critical to elucidate the underlying molecular mechanism of AML development and progression, which will contribute to the development of effective therapeutic strategies for AML.

MicroRNAs (miRNAs/miRs) are a class of small noncoding RNAs with a length of about 22 nucleotides and expressed in nearly all kinds of cells and tissues (8). miRNAs have been demonstrated to regulate gene expression post-transcriptionally via specifically binding to the 3'-UTR region of target mRNAs for degradation (9,10). In the past decades, a vast of evidence indicates that miRNAs exert vital functions in various biological processes, such as cell proliferation, apoptosis, migration and invasion (11). There was a close relationship between miRNA expression and human cancers, including lung cancer (12), bladder cancer (13), hepatocellular carcinoma (14) and AML (15). miRNAs could regulate the development and progression of cancers through serving as oncogenes or tumor suppressors (16). Aberrant expression of miRNAs is often observed in human cancer. Therefore, it is important to define the function and mechanism of miRNAs involved in cancers.

miR-135a has been reported to serve as tumor suppressor or an oncogene in different cancers. However, the role of miR-135a in AML remains largely unknown. In the present study, we found that miR-135a was downregulated in AML samples and its low expression predicted poor prognosis. Furthermore, we found that miR-135a overexpression inhibited the proliferation and induced apoptosis of AML cells. miR-135a could arrest AML cell cycle progression. In mechanism, we showed that miR-135a directly targeted HOXA10, whose restoration rescued the effects of miR-135a mimic transfection in AML cells. Taken together, our study identified miR-135a as a tumor suppressor in AML by targeting HOXA10, and miR-135a may be a promising prognostic biomarker for AML patients.
suppressor in AML by targeting HOXA10 and a prognostic marker for AML patients.

Materials and methods

Clinical specimens. All the blood samples from AML patients (n=29) and the normal volunteers (n=11) were obtained from the Second Affiliated Hospital of Harbin Medical University (Harbin, China). All the patients were diagnosed as AML according to the pathological and clinic features. The normal volunteers were the healthy persons without any diseases. Informed consent was obtained from each patient, and the research protocols were approved by the Ethics Committee of the Second Affiliated Hospital of Harbin Medical University (Harbin, China).

Cell culture and transfection. AML cell lines including HL60, AML193, AML2, AML5 and HS-5 normal cells from marrow stroma were primarily purchased from ATCC and maintained in Eagle's Minimum Essential Medium, supplemented with 10% fetal bovine serum (both from Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.) at 37˚C, 5% CO₂. Cell transfection was conducted using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol.

The coding sequence of HOXA10 was amplified from human cDNA and inserted into pcDNA6.1 (Invitrogen; Thermo Fisher Scientific, Inc.) vectors. miR-135a mimic (5'-AGU GUA AUU CUG GUA AUU UC-3'), miR-135a inhibitor (5'-UCA CAU AGG AUA AA AAG CCU-3') and mimic controls (5'-AUUU UCUCCGAAGCUCACGUAG-3') were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China) and used at a final concentration of 25 nmol/l. Cell transfection was performed by using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol.

Cell proliferation assay. AML5 and HL60 cells were transfected with miR-135a mimics or miR-NC for 36 h, then cells were harvested, washed with PBS, and centrifuged at 500 g at 4˚C for 10 min. Then cells were incubated with Annexin V in the dark for 15 min, propidium iodide (PI) was added 5 min before the end of incubation. After centrifugation for 5 min, cells were resuspended using PBS and FACS was performed on a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). The effect of miR-135a on cell cycle was further assessed as well. After transfection, cells were washed with PBS, fixed with 75% ethanol for 1 h at -20˚C. After washing with PBS, cells were incubated in PI solution for 20 min at RT. Then cells were analyzed with fluorescence-activated cell sorting (FACS).

Western blot analysis. Proteins were extracted from whole cell lysates and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, then transferred to a polyvinylidene fluoride (PVDF) membrane. The following primary antibodies were used: anti-cyclin D1 (1:1,000; cat. no. 2978) and anti-cyclin E1 (1:1,000; cat. no. 20808; both from Cell Signaling Technology, Inc., Danvers, MA, USA), anti-HOXA10 (1:1,000, cat. no. SAB2101061; Sigma-Aldrich; Merck KGaA), anti-PCNA (1:3,000; cat. no. 13110) and mouse anti-GAPDH (1:5,000; cat. no. 5174; both from Cell Signaling Technology, Inc.). Membranes were incubated with primary antibodies at 4˚C overnight, followed by incubation with the horseradish peroxidase-conjugated secondary anti-bodies (1:5,000; Abcam, Cambridge, MA, USA) for 1 h at 25˚C. Ultimately, the membrane was treated with chemiluminescence reagents (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) according to the manufacturer's instructions, and the image was analyzed.

Luciferase reporter assay. The potential miRNA binding sites of miR-135a predicted by computer-aided algorithms were obtained from microRNA.org target program (www.microRNA.org). The wild-type 3'-UTR of HOXA10 predicted to interact with miR-135a, together with mutant binding sequence within the predicted target sites, were synthesized by Shanghai GenePharma Co., Ltd., inserted into the pmirGLO Dual-Luciferase vector (Promega Corporation, Madison, WI, USA). AML cells were cotransfected with 500 ng of the luciferase construct along with miR-135a and miR-135a control using Lipofectamine™ 2000 reagent, in accordance with the manufacturer's protocol. Following cultivation for 48 h, the transfected cells were collected and evaluated for luciferase activity using a Dual Luciferase Reporter Assay kit (Promega Corporation) in accordance with the manufacturer's manual. The activity of firefly luciferase was normalized to analyzed on the basis of the 2^ΔΔCt method (17). The primers used were synthesized and purchased from Genecopeia (Guangzhou, China). The primer sequences were as follows: universal miRNA qRT-PCR primer (5'-AACGAGACGAC AGACAGAC-3'), U6 (5'-GCA ATTCGTTGAAGCGTTCCA TA-3'), miR-135a (5'-TATGCCCCCTTTATCTATG-3'), HOXA10 (forward, 5'-ATCTGCTCCCTTCGGCCAA AT-3' and reverse, 5'-CTGATGACGGAGTACCCAA-3') and 18S (forward, 5'-ATCAAACACCCGCTAGC-3' and reverse, 5'-CCCCGTACCCCTGTTGATCA-3').
that of Renilla luciferase. The results were obtained from three independent experiments performed in duplicate.

**Statistical analysis.** Each experiment was repeated at least three times. All data are expressed in terms of means ± the SD. The Kaplan-Meier method was used to calculate the survival curve, and log-rank test to determine statistical significance. The differences between groups were analyzed using two-tail Student's t-test or one-way ANOVA followed by Tukey's post hoc test. P<0.05 was considered statistically significant.

**Results**

**miR-135a is downregulated in AML.** In order to explore the cellular functions of miR-135a in AML, we firstly determined the expression of miR-135a in blood samples with AML by qRT-PCR. We found that the expression of miR-135a was significantly downregulated in AML samples compared to normal samples (Fig. 1A). Besides, miR-135a levels in AML cell lines were also lower than in normal cell line (HS-5) (Fig. 1B). Then we divided these AML samples into two subgroups base on miR-135a levels and performed Kaplan-Meier curve analysis. We found that higher expression of miR-135a in AML patients predicted better prognosis (Fig. 1C). These results suggested that miR-135a may exert a role in human AML progression and serve as a predictor for patients' prognosis.

**miR-135a inhibits cell proliferation and induces apoptosis in AML.** From Fig. 1B, we knew that miR-135a levels were relative lower in HL60 and AML5 cells than other cell lines. Therefore, we chose these two cell lines for further analysis. We overexpressed miR-135a in HL60 and AML5 cells through transfection with miR-135a mimics or controls. (D) Cell apoptosis was determined by fluorescence-activated cell sorting in HL60 and AML5 cells stained with Annexin V/PI. (E) Relative expression of miR-135a in HL60 and AML5 cells by qRT-PCR. (F) CCK-8 assays were performed to evaluate cell proliferation. Cellular viability was determined 72 h after transfection. The results represented three independent experiments and were expressed as mean ± SD. *P<0.05 vs. the control group.
miR-135a suppresses cell cycle progression. Cell proliferation was directly influenced by cell cycle. Therefore, we analyzed the effect of miR-135a on cell cycle by FACS. We found that overexpression of miR-135a significantly increased the numbers of HL60 and AML5 cells in G0/G1 phase (Fig. 3A and B). However, the HL60 and AML5 cells in S and G2/M phase were significantly decreased after miR-135a overexpression (Fig. 3A and B). Moreover, through western blot, we found that overexpression of miR-135a significantly reduced the protein levels of cyclin E1, cyclin D1 and PCNA in HL60 and AML5 cells (Fig. 3C), which indicated that miR-135a overexpression significantly inhibited cell cycle progression.

HOXA10 is a target of miR-135a. To search the target genes of miR-135a in AML cells, we used online prediction software (TargetScan 7.0 and miRBase) to look for the most possible target genes. Among all results, HOXA10 ranked top and has been reported to promote AML progression. Therefore, we chose them for following validation. There was a potential binding site of miR-135a in the 3'-UTR region of HOXA10 mRNA (Fig. 4A). Then we performed luciferase reporter assays. Results showed that the luciferase activity of WT-3'UTR HOXA10 in HL60 and AML5 cells was significantly downregulated by overexpression of miR-135a while no change was observed in the mutated 3'UTR transfection (Fig. 4B and C). Furthermore, qRT-PCR and western blot analysis indicated that overexpression of miR-135a significantly downregulated the mRNA and protein levels of HOXA10 in HL60 and AML5 cells. The results represented three independent experiments and were expressed as mean ± SD. *P<0.05 vs. the control group.
miR-135a is negatively associated with HOXA10 expression in AML. To further confirm the relationship of miR-135a and HOXA10 in AML cells, we analyzed the expression patterns of HOXA10 in AML sample cells by qRT-PCR. We found that HOXA10 expression was upregulated in AML sample cells compared to normal cells (Fig. 5A). Moreover, we found that HOXA10 mRNA level was negatively correlated with miR-135a expression in AML samples (Fig. 5B). These data further confirmed that miR-135a directly targeted HOXA10 in AML cells.

Restoration of HOXA10 reversed the effects of miR-135a overexpression. We have demonstrated HOXA10 was a direct target of miR-135a in AML cells. In order to determine whether miR-135a suppressed the proliferation and promoted apoptosis of AML cells through HOXA10, HL60 and AML5 cells were transduced with HOXA10. Western blot analysis results indicated that HOXA10 expression was significantly upregulated in HL60 and AML5 cells (Fig. 6A). Then cell survival ability was examined by CCK-8 assays in HL60 and AML5 cells. Results indicated that miR-135a overexpression decreased the survival ability and promoted cell apoptosis in HL60 and AML5 cells while restoration of HOXA10 significantly abrogated these effects of miR-135a overexpression (Fig. 6B and C). Taken together, our data demonstrated that miR-135a suppressed AML cell proliferation and induced apoptosis through directly targeting HOXA10.

Discussion

AML is one the most malignant cancers and the pathogenesis of AML need to be elucidated. miRNAs have been reported to participate in the development and progression of almost all kinds of human cancers, including breast cancer (18), cervical cancer (19), gastric cancer (20) and AML (15). Therefore, elucidating the mechanism of miRNA function will be crucial for the development of therapeutic strategies. Several miRNAs have been demonstrated to exert important roles on AML progression. For example, Wan et al reported that miR-103 confers the resistance to long-treatment of Adriamycin to human leukemia cells by regulation of COP1 (21). Liu et al showed that miR-34a induced apoptosis and suppressed autophagy through targeting HMGB1 in AML cells (22). Wang et al reported that upregulation of miR-125b suppresses the invasion and proliferation of human AML cells, and induced cellular apoptosis through regulating NF-κB pathway (23). Ke et al showed that miR-192 suppressed the proliferation, cell cycle transition of AML cells by targeting CCNT2 (24). In addition, Wang et al demonstrated that miR-183 enhanced the proliferation of pediatric AML cells by targeting programmed cell death 6 (25). miR-135a has been shown to aberrantly expressed in several cancer, including non-small cell lung cancer (26), thyroid carcinoma (27), glioblastoma (28), pancreatic cancer (29), hepatocellular carcinoma (30) and gastric cancer (31). However, the function of miR-135a in AML remains elusive. In this study, we showed that miR-135a expression was significantly downregulated in AML samples and cell lines. Moreover, the expression levels of miR-135a were correlated with the prognosis of AML patients. Furthermore, we demonstrated that miR-135a overexpression suppressed the proliferation and induced apoptosis of AML cells by targeting HOXA10.

HOXA10 belongs to the HOX gene superfamily encoding a class of transcription factors that regulate cell proliferation, differentiation and migration (32,33). Dysregulation of HOXA10 has been observed in several cancers, including...
ovarian cancer (34,35), colorectal cancer (36), oral squamous cell carcinoma (37), hepatocellular carcinoma (38), prostate carcinoma (39) and pancreatic cancer (40). As an oncogene, HOXA10 has also been demonstrated to promote the progression of human AML (41). In addition, Wang et al reported that constitutively active SHP2 cooperates with HoxA10 overexpression to induce AML (42). However, how HOXA10 expression was regulated by miRNAs in AML cells remains largely unknown. In our study, we found that HOXA10 was a direct target of miR-135a in AML cells. We showed that overexpression of miR-135a suppressed the luciferase activity of HOXA10 3'UTR in HL60 and AML5 cells. And miR-135a overexpression significantly reduced the mRNA and protein levels of HOXA10 in HL60 and AML5 cells. Furthermore, we also showed that HOXA10 expression was upregulated and negatively correlated with that of miR-135a in AML sample. Then through functional experiments, we found that overexpression of HOXA10 significantly reversed the effects of miR-135a transfection on AML cell proliferation and apoptosis. These results indicated that HOXA10 serves as an oncogene and is critical for the function of miR-135a in AML.

In conclusion, our study elucidated the essential role of miR-135a in AML progression and demonstrated its functional mechanism that miR-135a suppressed AML proliferation and induced apoptosis of AML cell through targeting HOXA10. Our study indicated that HOXA10 could act as a prognostic predictor for AML patients and might be a promising therapeutic target for AML treatment.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors' contributions
HX initiated, designed this work, analyzed, interpreted the results and wrote this manuscript. QW performed the experiments. All authors read and approved the final manuscript.

Ethics approval and consent to participate
For the use of human samples, the protocol for this study was approved by the Institutional Ethics Committee of The Second Affiliated Hospital of Harbin Medical University and all enrolled patients signed a written informed consent document.

Consent for publication
All patients within this study provide consent for the publication of their data.

Competing interests
The authors declare that they have no competing interests.

References


